Directorio

Es posible que algunos contenidos no estén disponibles en español.
433 clinical trials found.
Hematologic Malignancies and Cellular Therapy

We are doing this study to find the most effective, safe dose of an experimental drug called GC012F (the study drug) for adults who have relapsed/refractory multiple myeloma.

Compensation: No
Ages: 18-110
Oncology
Duke University Hospital
Genitourinary Cancer

We are doing this study to find the most effective, safe dose of an experimental drug called V940 (the study drug) when it is given with pembrolizumab to people who have had surgery to remove their bladder, kidney, or other organs for muscle-invasive urothelial carcinoma. We want to know how well this combination works compared to taking pembrolizumab on its own.

Compensation: No
Oncology
Primary Brain and Spinal Cord Tumors

We are doing this study to find out if the experimental combination and use of the drugs nivolumab and relatlimab can provide a benefit for people who are newly diagnosed with isocitrate dehydrogenase (IDH) wildtype glioblastoma (ndGBM).

Compensation: No
Ages: 18-110
Oncology
Duke University Hospital
Brain, Spinal Cord and Nerves

We are doing this study to find out if an experimental drug called CVN424 (the study drug) can help people diagnosed with advanced Parkinson's Disease (PD) who are on a stable dose of medication and continue to experience three of more hours of "OFF-time." OFF-time is a term that refers to the time when people experience PD symptoms between doses of medicine. We want to know if the study drug can reduce symptoms and lower that amount of time.

Compensation: Yes
Ages: 30-110
Non-Oncology
Other
Hematologic Malignancies and Cellular Therapy

We are doing this study to find out if continued use of an experimental drug called bomedemstat (the study drug) can provide an extended benefit for people with myeloproliferative neoplasms. We are enrolling people who have been in a previous study using the study drug and received a positive benefit.

Compensation: No
Ages: 18-110
Oncology
Duke University Hospital
Hematologic Malignancies and Cellular Therapy

We are doing this study to find out if an investigational drug called fostamatinib (the study drug) is beneficial for cGvHD when it is used in combination with a standard of care drug, ruxolitinib. We want to know if the study drug can improve relief from cGvHD symptoms.

Compensation: No
Oncology
Phase I

We are doing this study to find out if an experimental drug called PHTS001 (the study drug) is a safe and effective option for people who have advanced relapsed or refractory solid tumors.

Compensation: No
Ages: 18-110
Oncology
Duke University Hospital
Breast Cancer

We are doing this study to find out if the combination of two hormonal drugs, giredestrant and fulvestrant, are a safe and effective option if they are given with the study doctor's choice of a class of medicines called CDK4/6 inhibitors to people who have ER-positive, HER2-negative breast cancer that is resistant to standard treatments.

Compensation: No
Oncology